Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors | News

LEBANON, N.H., Nov. 24, 2020 /PRNewswire/ — Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies. Dr. Langer was a Senior Vice President at GlaxoSmithKline plc, served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy’s North American business. He is currently a director of Myriad Genetics, Inc., and was previously a director of Dicerna Pharmaceuticals, Inc. and Sirna Therapeutics, Inc.. Dr. Langer is a graduate of Columbia University, and earned an M.D. at Georgetown University School of Medicine and a J.D. at Harvard Law School.

“We are very fortunate to have Dennis’ counsel and unique skill set to help our team and board as we evolve our promising science towards creating cures for solid tumor cancer patients,” said Steven Yecies, Javelin’s Chief Executive Officer. “His track record and experience in moving promising science to ground-breaking therapies that help patients is a great match for Javelin’s needs. Dennis is a great example of the talent that we seek to surround ourselves with at Javelin and we look forward to his contributions. “

“Javelin has innovative and very promising immune-oncology technology and has assembled strong leadership in its management and on the board,” stated Dr. Langer. “I look forward to working with the company to advance the technology and make a difference for patients with solid cancers.”

More information about Dennis Langer is available at www.javelinoncology.com.

About Javelin Oncology

Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own proprietary efforts as well to create a services business to accelerate the science and use of precision immune medicine for others.

Learn more about Javelin Oncology at www.javelinoncology.com.

Contact info
Steven Yecies
CEO, Javelin Oncology
[email protected]

Source Article

Read more

Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors

LEBANON, N.H., Nov. 24, 2020 /PRNewswire/ — Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies. Dr. Langer was a Senior Vice President at GlaxoSmithKline plc, served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy’s North American business. He is currently a director of Myriad Genetics, Inc., and was previously a director of Dicerna Pharmaceuticals, Inc. and Sirna Therapeutics, Inc.. Dr. Langer is a graduate of Columbia University, and earned an M.D. at Georgetown University School of Medicine and a J.D. at Harvard Law School.

“We are very fortunate to have Dennis’ counsel and unique skill set to help our team and board as we evolve our promising science towards creating cures for solid tumor cancer patients,” said Steven Yecies, Javelin’s Chief Executive Officer. “His track record and experience in moving promising science to ground-breaking therapies that help patients is a great match for Javelin’s needs. Dennis is a great example of the talent that we seek to surround ourselves with at Javelin and we look forward to his contributions. “

“Javelin has innovative and very promising immune-oncology technology and has assembled strong leadership in its management and on the board,” stated Dr. Langer. “I look forward to working with the company to advance the technology and make a difference for patients with solid cancers.”

More information about Dennis Langer is available at www.javelinoncology.com.

About Javelin Oncology

Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own proprietary efforts as well to create a services business to accelerate the science and use of precision immune medicine for others.

Learn more about Javelin Oncology at www.javelinoncology.com.

Contact info
Steven Yecies
CEO, Javelin Oncology
[email protected]

SOURCE Javelin Oncology

Related Links

https://javelinoncology.com/

Source Article

Read more

The Alliance for Regenerative Medicine Announces Election of 2021 Officers, Executive Committee, and Board of Directors

Washington, DC, Oct. 21, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, announced today the election of its 2021 Officers, Executive Committee, and Board of Directors.

The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. The committee and board are subject to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.

“We are pleased to welcome such an accomplished group of executives to the 2021 ARM board of directors,” said Janet Lambert, CEO of ARM. “As scientists, commercial leaders, and regulatory experts, the new members of the board will be instrumental in helping ARM and its members deliver transformative and potentially curative regenerative medicines to patients around the world.” 

ARM 2021 Officers:

Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics (Chairman)

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics (Vice Chairman)

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific (Secretary)

Devyn Smith, Ph.D. – COO, Sigilon Therapeutics (Treasurer)

ARM 2021 Executive Committee:
*new to the Executive Committee for 2021

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific 

* Miguel Forte, M.D., Ph.D. – CEO, Bone Therapeutics

Claudia Mitchell, MBA, Ph.D. – SVP, Product and Portfolio Strategy, Astellas Pharma

Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics 

Bob Smith, MBA – SVP, Global Gene Therapy Business, Pfizer Inc.

Devyn Smith, Ph.D. – COO, Sigilon Therapeutics

* Arthur Tzianabos, Ph.D. – President and CEO, Homology Medicines

* Christopher Vann – COO, Autolus Therapeutics 

ARM 2021 Board of Directors:
*new to the Board for 2021

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics

Ronald Bartek – Co-Founder and President, Friedreich’s Ataxia Research Alliance

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific

Bradley Campbell, MBA – President and COO, Amicus Therapeutics

Cindy Collins, MBA – President and CEO, Editas Medicine

* Maria Fardis, Ph.D., MBA – President and CEO, Iovance Biotherapeutics

Miguel Forte, M.D., Ph.D. – CEO, Bone Therapeutics

Jonathan Garen, M.S. – CBO, uniQure

* Bobby Gaspar, M.D., Ph.D. – CEO, Orchard Therapeutics

Michael Hunt, ACA – CFO, ReNeuron

Jerry Keybl, Ph.D. – Senior Director, Cell & Gene Therapy, MilliporeSigma

* Louise Rodino-Klapac, Ph.D. – SVP, Gene Therapy, Sarepta Therapeutics

Ann Lee, Ph.D. – SVP and Head of Cell Therapy Development & Operations, Bristol Myers Squibb

* Dave Lennon, Ph.D. – President, Novartis Gene Therapies

Bruce Levine, Ph.D. – Barbara and Edward Netter Professor in Cancer Gene Therapy, and Founding Director, Clinical Cell and Vaccine Production Facility, Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

John Maslowski, M.S. – President and CEO, Castle Creek Pharmaceuticals

Claudia Mitchell, MBA, Ph.D. – SVP, Product and Portfolio Strategy, Astellas Pharma

* Adora Ndu, PharmD,

Read more

National Kidney Foundation Appoints Johns Hopkins Nephrologist to Board of Directors

National Kidney Foundation Appoints Johns Hopkins Nephrologist to Board of Directors

PR Newswire

NEW YORK, Oct. 19, 2020

NEW YORK, Oct. 19, 2020 /PRNewswire/ — The National Kidney Foundation (NKF) is pleased to announce the appointment of nephrologist Dr. Sumeska Thavarajah of the Johns Hopkins University School of Medicine to its national Board of Directors.

The National Kidney Foundation (NKF) is pleased to announce the appointment of nephrologist Dr. Sumeska Thavarajah of the Johns Hopkins University School of Medicine to its national Board of Directors.
The National Kidney Foundation (NKF) is pleased to announce the appointment of nephrologist Dr. Sumeska Thavarajah of the Johns Hopkins University School of Medicine to its national Board of Directors.

Dr. Thavarajah is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine in the Division of Nephrology. She has a demonstrated commitment to increasing education and community awareness of kidney disease noted through her work with the foundation’s local office NKF Serving Maryland and Delaware (NKF MDDE).

“As a daughter of a nephrologist, I have grown up learning about the challenges and needs of those with kidney disease,” Dr. Thavarajah said. “I am excited by the opportunity to work with others committed to bettering the lives of those with kidney disease through education efforts and advocacy.”  

Dr. Thavarajah served as the NKF MDDE-Medical Advisory Board Chair from 2014 to 2020 and has been a member of the board since 2013. Much of her work at Johns Hopkins and the local NKF has focused on the development of patient education programs, including videos, live classes, and patient conferences with an emphasis on understanding kidney disease, dialysis modalities, and transplant options.

“We look forward to having Sumeska’s voice on the Board as we work to advance kidney health in the United States,” said Anthony E. Tuggle, NKF Chair. “With 37 million adults in the U.S. affected by kidney disease, it has never been more important to get the attention of the 90 percent of those who don’t know they have it.”

Dr. Thavarajah is very involved in clinical care and operations serving as medical director for the nephrology clinic and acute dialysis services at Johns Hopkins Bayview Medical Center (JHBMC) and the FMC Merritt outpatient dialysis unit. Dr. Thavarajah joined the JHBMC Nephrology editorial board in October 2019 as a blog editor for the journal.

The NKF Board of Directors consists of leaders in their communities who have been affected by kidney disease. They are nephrologists, kidney healthcare professionals, living donors, transplant recipients, care partners, top executives with diverse business experience, and civic leaders. The Board meets three times per year and is charged with fiduciary, fundraising, and governance responsibilities for NKF. Board members serve a term of three years and may be elected for a second term.     

Kidney Disease Facts
In the United States, 37 million adults are estimated to have chronic kidney disease—and approximately 90 percent don’t know they have it.  One in 3 adults in the U.S. are at risk for chronic kidney disease.  Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of Black or

Read more